Therapeutic Controlled Release Strategies for Human Osteoarthritis

Overview

Journal Adv Healthc Mater

Specialties Biomedical Engineering
Biotechnology

Date 2024 Nov 7

PMID 39506433

Authors

Dan Wang

Wei Liu

Jagadeesh K Venkatesan

Henning Madry

Magali Cucchiarini

Affiliations

Soon will be listed here.

Abstract

Osteoarthritis is a progressive, irreversible debilitating whole joint disease that affects millions of people worldwide. Despite the availability of various options (non-pharmacological and pharmacological treatments and therapy, orthobiologics, and surgical interventions), none of them can definitively cure osteoarthritis in patients. Strategies based on the controlled release of therapeutic compounds via biocompatible materials may provide powerful tools to enhance the spatiotemporal delivery, expression, and activities of the candidate agents as a means to durably manage the pathological progression of osteoarthritis in the affected joints upon convenient intra-articular (injectable) delivery while reducing their clearance, dissemination, or side effects. The goal of this review is to describe the current knowledge and advancements of controlled release to treat osteoarthritis, from basic principles to applications in vivo using therapeutic recombinant molecules and drugs and more innovatively gene sequences, providing a degree of confidence to manage the disease in patients in a close future.

Citing Articles

Therapeutic Controlled Release Strategies for Human Osteoarthritis.

Wang D, Liu W, Venkatesan J, Madry H, Cucchiarini M Adv Healthc Mater. 2024; 14(2):e2402737.

PMID: 39506433 PMC: 11730424. DOI: 10.1002/adhm.202402737.

References

Kang M, Kim J, Im G . Thermoresponsive nanospheres with independent dual drug release profiles for the treatment of osteoarthritis. Acta Biomater. 2016; 39:65-78. DOI: 10.1016/j.actbio.2016.05.005. View

Hunziker E, Quinn T, Hauselmann H . Quantitative structural organization of normal adult human articular cartilage. Osteoarthritis Cartilage. 2002; 10(7):564-72. DOI: 10.1053/joca.2002.0814. View

Neogi T . The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage. 2013; 21(9):1145-53. PMC: 3753584. DOI: 10.1016/j.joca.2013.03.018. View

Mehta S, He T, Bajpayee A . Recent advances in targeted drug delivery for treatment of osteoarthritis. Curr Opin Rheumatol. 2020; 33(1):94-109. PMC: 8101446. DOI: 10.1097/BOR.0000000000000761. View

Bedingfield S, Colazo J, di Francesco M, Yu F, Liu D, Di Francesco V . Top-Down Fabricated microPlates for Prolonged, Intra-articular Matrix Metalloproteinase 13 siRNA Nanocarrier Delivery to Reduce Post-traumatic Osteoarthritis. ACS Nano. 2021; 15(9):14475-14491. PMC: 9074946. DOI: 10.1021/acsnano.1c04005. View

Matsiko A, Levingstone T, OBrien F . Advanced Strategies for Articular Cartilage Defect Repair. Materials (Basel). 2017; 6(2):637-668. PMC: 5452095. DOI: 10.3390/ma6020637. View

Ebada H, Nasra M, Nassra R, Abdallah O . Chondroitin sulfate-functionalized lipid nanoreservoirs: a novel cartilage-targeting approach for intra-articular delivery of cassic acid for osteoarthritis treatment. Drug Deliv. 2022; 29(1):652-663. PMC: 8865121. DOI: 10.1080/10717544.2022.2041130. View

Jarraya M, Guermazi A, Roemer F . Osteoarthritis year in review 2023: Imaging. Osteoarthritis Cartilage. 2023; 32(1):18-27. DOI: 10.1016/j.joca.2023.10.005. View

Delcassian D, Patel A, Cortinas A, Langer R . Drug delivery across length scales. J Drug Target. 2018; 27(3):229-243. DOI: 10.1080/1061186X.2018.1438440. View

10.

Huang X, Brazel C . On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001; 73(2-3):121-36. DOI: 10.1016/s0168-3659(01)00248-6. View

11.

Peppas N, Clegg J . The challenge to improve the response of biomaterials to the physiological environment. Regen Biomater. 2016; 3(2):67-71. PMC: 4817319. DOI: 10.1093/rb/rbw012. View

12.

Khan N, Haqqi T . Epigenetics in osteoarthritis: Potential of HDAC inhibitors as therapeutics. Pharmacol Res. 2017; 128:73-79. PMC: 5803377. DOI: 10.1016/j.phrs.2017.08.007. View

13.

Migliore A, Paoletta M, Moretti A, Liguori S, Iolascon G . The perspectives of intra-articular therapy in the management of osteoarthritis. Expert Opin Drug Deliv. 2020; 17(9):1213-1226. DOI: 10.1080/17425247.2020.1783234. View

14.

Lan Q, Lu R, Chen H, Pang Y, Xiong F, Shen C . MMP-13 enzyme and pH responsive theranostic nanoplatform for osteoarthritis. J Nanobiotechnology. 2020; 18(1):117. PMC: 7450974. DOI: 10.1186/s12951-020-00666-7. View

15.

Mohammadi S, Salehi M, Jahanshahi A, Shahrabi Farahani M, Zakavi S, Behrouzieh S . Artificial intelligence in osteoarthritis detection: A systematic review and meta-analysis. Osteoarthritis Cartilage. 2023; 32(3):241-253. DOI: 10.1016/j.joca.2023.09.011. View

16.

Tellegen A, Rudnik-Jansen I, Utomo L, Versteeg S, Beukers M, Maarschalkerweerd R . Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients. Osteoarthritis Cartilage. 2022; 31(3):351-362. DOI: 10.1016/j.joca.2022.11.008. View

17.

Holyoak D, Wheeler T, van der Meulen M, Singh A . Injectable mechanical pillows for attenuation of load-induced post-traumatic osteoarthritis. Regen Biomater. 2019; 6(4):211-219. PMC: 6683954. DOI: 10.1093/rb/rbz013. View

18.

Glyn-Jones S, Palmer A, Agricola R, Price A, Vincent T, Weinans H . Osteoarthritis. Lancet. 2015; 386(9991):376-87. DOI: 10.1016/S0140-6736(14)60802-3. View

19.

Zhang L, Peng H, Zhang W, Li Y, Liu L, Leng T . Yeast Cell wall Particle mediated Nanotube-RNA delivery system loaded with miR365 Antagomir for Post-traumatic Osteoarthritis Therapy via Oral Route. Theranostics. 2020; 10(19):8479-8493. PMC: 7392020. DOI: 10.7150/thno.46761. View

20.

Zhang Z, Mu Y, Zhou H, Yao H, Wang D . Cartilage Tissue Engineering in Practice: Preclinical Trials, Clinical Applications, and Prospects. Tissue Eng Part B Rev. 2023; 29(5):473-490. DOI: 10.1089/ten.TEB.2022.0190. View